# PolyPid (PYPD) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/PYPD
## Company Profile
- Ticker: PYPD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel
## Stock Data
- Close: 4.73 USD
- Market cap: 93377759.86 USD
- Last updated: 2026-08-11
## Business Overview
### Local Controlled-Release Therapeutics
PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden.
### PLEX Technology
The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over days or weeks.
### D-PLEX100
D-PLEX100 delivers doxycycline locally after abdominal colorectal surgery to prevent surgical-site infections. Its NDA is supported by the pivotal Phase 3 SHIELD II study, which met its primary and key secondary endpoints.
### Azurity Partnership
Azurity Pharmaceuticals holds U.S. and Canadian commercialization rights to D-PLEX100. PolyPid retains eligibility for development and commercial milestones plus tiered royalties.
## Why The Stock Is Moving

The latest monitored company update is “PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- FDA action on the D-PLEX100 NDA by the November 28, 2026 PDUFA goal date.
- Potential U.S. commercial launch of D-PLEX100 by Azurity in early 2027, subject to approval.

## Recent News
- 2026-08-12 11:30 EST — [PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/PYPD/polypid-provides-corporate-update-and-reports-second-quarter-2026-financial-resu-5a5c27f0) — Source: PolyPid
- 2026-07-30 12:00 EST — [PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026](https://biopharmsignal.com/news/PYPD/polypid-to-report-second-quarter-2026-financial-results-and-operational-highligh-77e27a6e) — Source: PolyPid
- 2026-07-29 12:30 EST — [PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀](https://biopharmsignal.com/news/PYPD/polypid-announces-fda-acceptance-of-nda-with-priority-review-for-d-plex-d8b950d0) — Source: PolyPid
- 2026-07-21 11:30 EST — [PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada](https://biopharmsignal.com/news/PYPD/polypid-announces-exclusive-partnership-with-azurity-pharmaceuticals-for-the-com-acf32640) — Source: PolyPid
- 2026-06-01 12:30 EST — [PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀](https://biopharmsignal.com/news/PYPD/polypid-completes-new-drug-application-submission-to-fda-for-d-plex) — Source: PolyPid